The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms

Elotuzumab is a humanized therapeutic monoclonal antibody directed to the surface glycoprotein SLAMF7 (CS1, CRACC, CD319), which is highly expressed on multiple myeloma (MM) tumor cells. Improved clinical outcomes have been observed following treatment of MM patients with elotuzumab in combination w...

Full description

Bibliographic Details
Main Authors: Tatiana Pazina, Ashley M. James, Alexander W. MacFarlane, Natalie A. Bezman, Karla A. Henning, Christine Bee, Robert F. Graziano, Michael D. Robbins, Adam D. Cohen, Kerry S. Campbell
Format: Article
Language:English
Published: Taylor & Francis Group 2017-09-01
Series:OncoImmunology
Subjects:
adcc
elotuzumab
multiple myeloma
nk cells
slamf7
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1339853

Internet

http://dx.doi.org/10.1080/2162402X.2017.1339853

Similar Items